Industry Advisors Framework
An Expert Network Behind Every Transaction
To complement our investment banking team, Emani Capital Advisory leverages an expert network of Senior Industry Advisors providing critical technical diligence, market validation, and operational insights.
SP
Shiva Prakash
Industry Advisor - Transaction Structuring & Due Diligence
A Chartered Accountant and Founding Partner of Mukunda Shiva & Associates, Shiva Prakash brings over 19 years of experience in transaction structuring, financial and commercial due diligence, corporate structuring, tax advisory, and regulatory compliance, following earlier roles at Ernst & Young and IBM. He strengthens Emani Capital Advisory's transaction structuring and due diligence support across mandates.
AB
Anand Bhogu
Industry Advisor - Biotechnology
With over two decades of experience across biotechnology and biopharmaceutical research and development, including generics and complex generics, Anand Bhogu has led drug discovery-linked business development, strategic partnerships, key account management, and sales strategy across regulated markets including the US, EU, UK, China, Brazil, and Africa, with senior roles spanning Lotus Labs (Teva Group), Aizant Drug Research Solutions, and Lambda Therapeutic Research. He supports the firm's diligence and market positioning for biotechnology, biopharmaceutical R&D, and clinical research mandates.
SR
B. Suman Rao
Industry Advisor - Pharmaceuticals
B. Suman Rao is a senior biopharmaceutical executive with over 25 years of global experience driving quality compliance, regulatory strategy, and technical operations across the pharma and biologics sectors. He has held marquee leadership roles across premier organizations, including Sanzyme Group, Aurobindo Pharma, Eugia Pharma, Amneal Oncology, Cronus Pharma.
Suman specializes in navigating the complexities of advanced therapeutics - including sterile formulations, oncology, biologicals, and biosimilars. Over his distinguished career, he has successfully managed multi-site operations, spearheaded large-scale digital transformations, and repeatedly secured zero-observation USFDA, EU, and PIC/S regulatory clearances.
